Buprenorphine for Opioid Addiction in Pregnancy: No Added Risk of ADHD or Autism in Children

Is Buprenorphine Safe to Use During Pregnancy?

Buprenorphine, a partial opioid agonist widely used in medication-assisted treatment (MAT) for opioid use disorder, has long been recommended by organizations including the American College of Obstetricians and Gynecologists (ACOG) and the World Health Organization as a first-line treatment during pregnancy. The rationale is straightforward: untreated opioid addiction carries far greater risks — including preterm birth, placental abruption, and maternal overdose death — than the known effects of supervised buprenorphine therapy.

New research now provides additional reassurance by examining long-term neurodevelopmental outcomes in children whose mothers received buprenorphine during pregnancy. The study found that rates of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder were comparable between children with prenatal buprenorphine exposure and those without. This addresses a lingering concern among both patients and clinicians that opioid-based medications, even therapeutic ones, might affect fetal brain development in ways that manifest years later.

What Are the Risks of Untreated Opioid Addiction During Pregnancy?

The opioid crisis continues to affect pregnant populations disproportionately. According to the CDC, opioid use disorder during pregnancy has increased significantly over the past two decades. Untreated addiction exposes both mother and fetus to cycles of intoxication and withdrawal, which can trigger preterm labor, fetal distress, and stillbirth. Abrupt discontinuation of opioids — sometimes attempted out of concern for the baby — can be equally dangerous, as withdrawal itself poses risks to the pregnancy.

Medication-assisted treatment with buprenorphine or methadone stabilizes opioid levels, reduces illicit drug use, and improves prenatal care engagement. While neonatal abstinence syndrome (NAS) — a treatable withdrawal condition in newborns — can occur with both medications, studies have generally found that buprenorphine is associated with shorter NAS duration and reduced need for pharmacological treatment compared to methadone. The new neurodevelopmental findings further strengthen the evidence base supporting buprenorphine as a safe and effective option throughout pregnancy.

What Does This Mean for Clinical Practice and Patients?

Stigma remains one of the greatest barriers to effective treatment for opioid use disorder in pregnancy. Many expectant mothers fear that taking any opioid medication — even one prescribed under medical supervision — could harm their child's brain development. This fear, combined with societal judgment, leads some women to avoid or discontinue treatment, with potentially devastating consequences. Evidence showing no excess risk of ADHD or autism can help clinicians have more confident, reassuring conversations with patients.

From a public health perspective, these results align with the broader push to expand access to buprenorphine. In the United States, recent policy changes have removed the requirement for a special DEA waiver (the X-waiver) to prescribe buprenorphine, making it easier for general practitioners and obstetricians to offer treatment directly. As the evidence for safety accumulates — both in the short term with neonatal outcomes and now in the longer term with child development — the case for integrating buprenorphine into routine prenatal care for affected patients becomes increasingly compelling.